STOCK TITAN

[8-K] Pulmatrix, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Pulmatrix, Inc. furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025, along with a corporate update. The press release is provided as Exhibit 99.1 and incorporated by reference.

Consistent with General Instruction B.2 to Item 2.02, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.

Pulmatrix, Inc. ha fornito un 8-K annunciando di aver emesso un comunicato stampa con i risultati finanziari del terzo trimestre fiscale terminato il 30 settembre 2025, insieme a un aggiornamento aziendale. Il comunicato stampa è fornito come Esibizione 99.1 e incorporato per riferimento.

In linea con l'Istruzione Generale B.2 relativa all'Voce 2.02, le informazioni contenute in questo rapporto, inclusa l'Esibizione 99.1, sono fornite e non ritenute depositate ai sensi del Securities Exchange Act.

Pulmatrix, Inc. presentó un 8-K anunciando que emitió un comunicado de prensa con los resultados financieros del tercer trimestre fiscal terminado el 30 de septiembre de 2025, junto con una actualización corporativa. El comunicado de prensa se proporciona como Exhibit 99.1 e incorporado por referencia.

De acuerdo con la Instrucción General B.2 de la Sección 2.02, la información en este informe, incluida la Exhibit 99.1, se proporciona y no se considera presentada conforme a la Exchange Act.

Pulmatrix, Inc. 는 2025년 9월 30일에 종료된 제3 회계연도 분기 실적과 함께 회사 업데이트를 담은 보도자료를 발표했다는 8-K를 제출했다. 보도자료는 Exhibit 99.1로 제공되며 참조에 포함된다.

제2.02항의 일반 지침 B.2에 따라 이 보고서의 정보, 포함된 Exhibit 99.1은 Exchange Act에 따라 제출된 것으로 간주되지 않는다.

Pulmatrix, Inc. a fourni un 8-K annonçant qu'il avait émis un communique de presse avec les résultats financiers du troisième trimestre fiscal clos le 30 septembre 2025, ainsi qu'une mise à jour corporative. Le communiqué de presse est fourni comme Exhibit 99.1 et est incorporé par référence.

Conformément à l'Instruction Générale B.2 de l'Article 2.02, les informations contenues dans ce rapport, y compris l'Exhibit 99.1, sont fournies et ne sont pas jugées déposées en vertu de la loi Exchange Act.

Pulmatrix, Inc. hat eine 8-K vorgelegt, in der mitgeteilt wird, dass ein Pressemitteilung mit den finanziellen Ergebnissen des dritten Geschäftsjahresquartals zum 30. September 2025 veröffentlicht wurde, zusammen mit einem Unternehmensupdate. Die Pressemitteilung wird als Exhibit 99.1 bereitgestellt und durch Verweis einbezogen.

Im Einklang mit Allgemeiner Hinweis B.2 zu Punkt 2.02 werden die Informationen in diesem Bericht, einschließlich Exhibit 99.1, als bereitgestellt angesehen und nicht im Sinne des Exchange Act eingereicht.

Pulmatrix, Inc. قدمت نموذج 8-K يعلن إصدارها بياناً صحفياً بنتائجها المالية للربع المالي الثالث المنتهي في 30 سبتمبر 2025، مع تحديث الشركات. يُقدَم البيان الصحفي كـ Exhibit 99.1 ومُدرج بالمرجعية.

وفقاً للتعليمات العامة B.2 للبند 2.02، فإن المعلومات الواردة في هذا التقرير، بما فيها Exhibit 99.1، هي مقدَّمة وليست مُعدة وفق قانون الأوراق المالية Exchange Act.

Pulmatrix, Inc. 发布了一份8-K,宣布发布的新闻稿显示截至2025年9月30日的第三财季财务业绩,以及一份公司更新。新闻稿作为Exhibit 99.1提供并被引用。

依据一般指示 B.2至项目 2.02 的规定,本报告中的信息(包括 Exhibit 99.1)是被提供的,而不被视为根据证券交易法(Exchange Act)提交。

Positive
  • None.
Negative
  • None.

Pulmatrix, Inc. ha fornito un 8-K annunciando di aver emesso un comunicato stampa con i risultati finanziari del terzo trimestre fiscale terminato il 30 settembre 2025, insieme a un aggiornamento aziendale. Il comunicato stampa è fornito come Esibizione 99.1 e incorporato per riferimento.

In linea con l'Istruzione Generale B.2 relativa all'Voce 2.02, le informazioni contenute in questo rapporto, inclusa l'Esibizione 99.1, sono fornite e non ritenute depositate ai sensi del Securities Exchange Act.

Pulmatrix, Inc. presentó un 8-K anunciando que emitió un comunicado de prensa con los resultados financieros del tercer trimestre fiscal terminado el 30 de septiembre de 2025, junto con una actualización corporativa. El comunicado de prensa se proporciona como Exhibit 99.1 e incorporado por referencia.

De acuerdo con la Instrucción General B.2 de la Sección 2.02, la información en este informe, incluida la Exhibit 99.1, se proporciona y no se considera presentada conforme a la Exchange Act.

Pulmatrix, Inc. 는 2025년 9월 30일에 종료된 제3 회계연도 분기 실적과 함께 회사 업데이트를 담은 보도자료를 발표했다는 8-K를 제출했다. 보도자료는 Exhibit 99.1로 제공되며 참조에 포함된다.

제2.02항의 일반 지침 B.2에 따라 이 보고서의 정보, 포함된 Exhibit 99.1은 Exchange Act에 따라 제출된 것으로 간주되지 않는다.

Pulmatrix, Inc. a fourni un 8-K annonçant qu'il avait émis un communique de presse avec les résultats financiers du troisième trimestre fiscal clos le 30 septembre 2025, ainsi qu'une mise à jour corporative. Le communiqué de presse est fourni comme Exhibit 99.1 et est incorporé par référence.

Conformément à l'Instruction Générale B.2 de l'Article 2.02, les informations contenues dans ce rapport, y compris l'Exhibit 99.1, sont fournies et ne sont pas jugées déposées en vertu de la loi Exchange Act.

Pulmatrix, Inc. hat eine 8-K vorgelegt, in der mitgeteilt wird, dass ein Pressemitteilung mit den finanziellen Ergebnissen des dritten Geschäftsjahresquartals zum 30. September 2025 veröffentlicht wurde, zusammen mit einem Unternehmensupdate. Die Pressemitteilung wird als Exhibit 99.1 bereitgestellt und durch Verweis einbezogen.

Im Einklang mit Allgemeiner Hinweis B.2 zu Punkt 2.02 werden die Informationen in diesem Bericht, einschließlich Exhibit 99.1, als bereitgestellt angesehen und nicht im Sinne des Exchange Act eingereicht.

false 0001574235 0001574235 2025-10-16 2025-10-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 16, 2025

 

PULMATRIX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36199   46-1821392

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

945 Concord Street, Suite 1217

Framingham, MA 01701

(Address of principal executive offices) (Zip Code)

 

(888) 355-4440

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   PULM   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On October 16, 2025, Pulmatrix, Inc. issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated October 16, 2025*
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

* This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PULMATRIX, INC.
     
Date: October 16, 2025 By: /s/ Peter Ludlum
    Peter Ludlum
    Interim Chief Executive Officer and Interim Chief Financial Officer

 

 

 

FAQ

What did Pulmatrix (PULM) disclose in this 8-K?

The company furnished a press release announcing financial results for the third fiscal quarter ended September 30, 2025, and provided a corporate update as Exhibit 99.1.

Which period does Pulmatrix’s (PULM) update cover?

The third fiscal quarter ended September 30, 2025.

Is the Pulmatrix (PULM) press release filed or furnished?

It is furnished pursuant to Item 2.02 and, under General Instruction B.2, is not deemed filed under the Exchange Act.

Where can I find the Pulmatrix (PULM) press release in the 8-K?

It is included as Exhibit 99.1 to the report.

Who signed the Pulmatrix (PULM) 8-K?

Peter Ludlum, Interim Chief Executive Officer and Interim Chief Financial Officer, signed the report.

What is Pulmatrix’s (PULM) trading symbol and exchange?

The common stock trades on The NASDAQ Stock Market LLC under the symbol PULM.
Pulmatrix

NASDAQ:PULM

PULM Rankings

PULM Latest News

PULM Latest SEC Filings

PULM Stock Data

16.95M
3.63M
0.66%
9.34%
0.2%
Biotechnology
Pharmaceutical Preparations
Link
United States
FRAMINGHAM